18F GP1

Drug Profile

18F GP1

Alternative Names: 18F-GPI; 18F-GP1; F18-GP1; GP1-18F; GP1-F18

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Piramal Imaging; University of Zurich
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Thrombosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Thrombosis(Diagnosis) in Switzerland (Parenteral, Injection)
  • 08 May 2017 University of Zurich and Piramal Imaging terminate a phase I trial for Thrombosis (Diagnosis) in Switzerland (NCT02469376) prior to May 2017
  • 14 Nov 2014 18F GP1 is available for licensing as of 14 Nov 2014. http://www.piramal.com/imaging/about-us/business-dev-licensing.html
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top